Product PortfolioOur approach is to achieve balance in the products that we develop through a portfolio comprised of innovative vaccines and therapeutics that target infectious diseases worldwide.
Licensed Product
BioThrax® (Anthrax Vaccine Adsorbed)
Investigational Products
Anthrax IG Therapeutic
Tuberculosis Vaccine
Typhella™ (Typhoid Vaccine Live Oral ZH9)
Recombinant Anthrax Vaccine (rPA)
Anthrax Monoclonal Antibody Therapeutic
Universal Flu Vaccine
Chlamydia Vaccine
To view information about Emergent product development, please refer to the Company’s Form 10-K.
ALL INVESTIGATIONAL PRODUCTS MUST SUCCESSFULLY COMPLETE THEIR RESPECTIVE DEVELOPMENT PROGRAMS AND BE APPROVED BY THE FDA (AND/OR FOREIGN EQUIVALENTS) BEFORE THEY MAY BE MARKETED.
|
